SCHEMBL15547477

SCHEMBL15547477

COc1ccc(C(=O)c2cc(CC(=O)NC(=N)N)c(-c3ccc(Cl)c(Cl)c3)s2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
RXFP1 Q9HBX9 1/20 0.48
MAPT P10636 6/20 0.40
CTSD P07339 1/20 0.39
KDM4E B2RXH2 2/20 0.37
PKM P14618 1/20 0.37
RCE1 Q9Y256 1/20 0.37
EIF4E P06730 1/20 0.37
HPGD P15428 4/20 0.36
LMNA P02545 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
RAB9A P51151 2/20 0.36
POLB P06746 2/20 0.36
NPC1 O15118 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
OPRD1 P41143 1/20 0.36
HTR2A P28223 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16893531 0.99 KMT2A (0.48) KMT2AMEN1RXFP1MAPTCTSD
SCHEMBL15546196 0.91 MEN1 (0.55) KMT2AMEN1RXFP1MAPTKDM4E
Hydrochloric Acid SCHEMBL16893371 0.90 MEN1 (0.54) KMT2AMEN1RXFP1MAPTKDM4E
SCHEMBL15545547 0.89 KMT2A (0.49) KMT2AMEN1RXFP1MAPTCTSD
SCHEMBL18035703 0.88 KMT2A (0.46) KMT2AMEN1RXFP1MAPTCTSD
SCHEMBL16893498 0.85 KMT2A (0.44) KMT2AMEN1RXFP1MAPTCTSD
SCHEMBL18035674 0.85 KMT2A (0.47) KMT2AMEN1RXFP1MAPTCTSD
SCHEMBL28819583 0.84 KMT2A (0.50) KMT2AMEN1RXFP1MAPTKDM4E
SCHEMBL15546009 0.84 KMT2A (0.66) KMT2AMEN1RXFP1MAPTKDM4E
SCHEMBL15546529 0.84 MEN1 (0.49) KMT2AMEN1RXFP1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2875010-B1 THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-08-31 EP claimed
EP-2875010-A1 THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES Metabrain Research (FR) 2015-05-27 EP claimed
WO-2014013181-A1 THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2014-01-23 WO claimed
US-9777015-B2 Useful thiophene derivatives in the treatment of diabetes METABRAIN RESEARCH (FR) 2017-10-03 US disclosed
EP-2875010-B1 THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-08-31 EP disclosed
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2015-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES SLC5A2, SLC5A1, TPMT KMT2A 4602/4885MEN1 4184/4885RXFP1 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.